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Plasmacytoid dendritic cells (pDCs) initiate both innate and adaptive immune responses, making them
attractive targets for post-transplantation immunotherapy, particularly after cord blood transplantation
(CBT). Toll-like receptor (TLR) agonists are currently studied for pDC stimulation in various clinical settings.
Their efﬁcacy depends on pDC number and functionality, which are unknown after CBT. We performed a
longitudinal study of pDC reconstitution in children who underwent bone marrow transplantation (BMT) and
single-unit CBT. Both CBT and unrelated BMT patients received antithymocyte globulin as part of their graft-
versus-host disease prophylaxis regimen. pDC blood counts were higher in CBT patients than in healthy
volunteers from 2 to 9 months after transplantation, whereas they remained lower in BMT patients. We
showed that cord blood progenitors gave rise in vitro to a 500-fold increase in functional pDCs over bone
marrow counterparts. Upon stimulation with a TLR agonist, pDCs from both CBT and BMT recipients upre-
gulated T cell costimulatory molecules, whereas interferon-alpha (IFN-a) production was impaired for
9 months after CBT. TLR agonist treatment is thus not expected to induce IFN-a production by pDCs after CBT,
limiting its immunotherapeutic potential. Fortunately, in vitro production of large amounts of functional pDCs
from cord blood progenitors paves the way for the post-transplantation adoptive transfer of pDCs.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is the
unique hope for cure for patients with chemotherapy-
refractory leukemia through the combined antileukemic
effects of the conditioning regimen and the donor-derived
immune response [1]. This immune graft-versus-leukemia
(GVL) effect is altogether due to T cells and natural killer
(NK) cells [2e5]. Many patients still relapse after trans-
plantation and the prognosis for high-risk patients remains
dismal [6]. Several approaches are, thus, currently underdgments on page 1506.
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14.06.007investigation to enhance this GVL effect. Among them, the
activation of immune cells involved in the early steps of
the immune cascade, such as plasmacytoid dendritic cells
(pDCs), is particularly appealing, as these cells are expected
to activate both innate and adaptive immunity. Indeed, upon
activation of their toll-like receptors (TLR), pDCs ﬁrst secrete
high amounts of interferon-alpha (IFN-a) and other cyto-
kines, leading to NK cell activation, and then they upregulate
T cell costimulatory molecules, allowing them to act as
antigen-presenting cells [7e11].
Synthetic DNA oligodeoxynucleotides containing unme-
thylated CpG motifs (CpG ODNs) have been shown to induce
strong immune stimulation and increase antitumor re-
sponses both in animal models and in humans [12e14]. CpG
ODNs mimic viral or bacterial DNA and bind TLR-9 in the
endosomal compartment of pDCs [12,14]. The safety and
activity of TLR-9 agonists are being explored in a wide rangeTransplantation.
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aimed at harnessing the immune response to ﬁght cancer
[15]. In particular, TLR-9 agonists could be used after HSCT to
increase the GVL effect [16]. To be effective, TLR-9 agonists
need the presence of functional pDCs to initiate immune
responses. It has been shown that pDC blood counts remain
below normal levels for 1 year after bone marrow (BM)
transplantation (BMT) and even lower in patients experi-
encing acute graft-versus-host disease (GVHD) [17,18].
However, the functional properties of post-HSCT pDCs have
not been explored and pDC count recovery has never been
studied after cord blood (CB) transplantation (CBT).
Indeed, CB is increasingly being chosen as a graft source
because of its immediate availability [19] and greater
tolerance to HLA disparity, as well as its lower incidence of
GVHD combined with a preserved GVL effect [20]. En-
hancing the GVL effect after CBT poses speciﬁc challenges, as
donor lymphocytes are not available for adoptive immuno-
therapy. Therefore, targeting cells involved early in the im-
mune cascade may be particularly well suited for post-CBT
immunotherapy.
To assess post-HSCT pDC reconstitution, we undertook
the ﬁrst longitudinal study of the recovery of pDC counts and
function in CBT and BMT patients. We enrolled 53 patients to
explore the recovery of pDC count and function after BMT
and CBT. The 2main functional hallmarks of pDCs after TLR-9
stimulation were assessed: the production of IFN-a, and theTable 1
Patient and Transplantation Characteristics
Characteristic Bone Marrow
No. of patients 17
Age at transplantation, median (range), yr 11.6 (6-17.4)
Sex, n (%)
Female 9 (53)
Male 8 (47)
Diseases, n (%)
Malignant 10 (59)
ALL 3
AML 5
CML 1
MDS/JMML 1
Neuroblastoma 0
Nonmalignant 7 (41)
Donors, n (%)
Related 12 (71)
Unrelated 5 (29)
Number of HLA mismatches, n (%)
0 16 (94)
1 1 (6)
2 0 (0)
Total nucleated cells infused, median (range), $ 108/kg 4.1 (2.5-5.3)
CD34þ cells infused, median (range), $ 106/kg 5.0 (.1-12.5)
Length of neutropenia, median (range), d 22 (10-25)
Length of thrombopenia, median (range), d 24 (0-82)
Acute GVHD (stages II-IV), n (%) 0 (0)
Chronic GVHD, n (%) 0 (0)
Relapse, n (%) 4 (24)
Time from transplantation (range), d (210-668)
Patients with EBV viremia, n (%) 11 (65)
Patients with CMV viremia, n (%) 0 (0)
Deaths, n (%) 1 (6)
From relapse 1
Other causes 0
ALL indicates acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CM
juvenile myelomonocytic leukemia; EBV, Epstein-Barr virus; CMV, cytomegaloviru
* P value: Fisher test for categoric variables and Mann-Whitney for continuousupregulation of T cell costimulatory molecules CD40, CD54,
CD80, and CD86.
METHODS
Patients
Written informed consent was obtained in accordance
with the Declaration of Helsinki after CHU Sainte Justine’s
institutional review board approval. Blood samples were
collected at 1, 2, 3, 6, 9, and 12 months after transplantation.
Fifty-three patients (19 BMT and 34 CBT) were enrolled be-
tween 2005 and 2010 (Table 1). Patients with donor chime-
rism < 90% at 1 month after transplantation were excluded
from the study (2 BMTand 6 CBT patients). pDC blood counts
were, thus, analyzed for 17 BMT and 28 CBT patients. In case
of leukemia relapse, data were censored at the time of
relapse. Grafts were not T cell depleted. All patients received
myeloablative reparative regimens, except for 3 patients in
CBT group and 3 patients in BMT group; 10 patients who
underwent CBT and 3 who underwent BMT received total
body irradiation. GVHD prophylaxis for related BMT patients
included a short course of methotrexate and cyclosporine for
6 months after transplantation. Unrelated BMT patients
received a short course of methotrexate, cyclosporine until
10 months after transplantation, and rabbit antithymocyte
globulin (ATG, Genzyme, Cambridge MA), 2 mg/kg, on
days 2, 1, þ1, þ2. All CBT patients were unrelated. They
received ATG, methylprednisolone followed by an oralTransplantation Cord Blood Transplantation P Value*
28
9.9 (.5-19.9) .06
.22
9 (32)
19 (68)
.16
23 (82)
12
4
1
5
1
5 (18)
<.0001
0 (0)
28 (100)
<.0001
3 (11)
16 (57)
9 (32)
.5 (.3-2.5) <.0001
.2 (.1-1.8) <.0001
22 (8-34) .42
47 (0-80) .0006
3 (11) .28
1 (4) 1.00
9 (32) .74
(68-1310)
19 (68) 1.00
6 (21) .07
7 (25) .13
6
1
L, chronic myeloblastic leukemia; MDS, myelodysplastic syndrome; JMML,
s.
variables.
Figure 1. Plasmacytoid dendritic cell counts after cord blood and bone
marrow transplantation. Lin CD123high HLA-DRþ plasmacytoid dendritic cell
(pDC) counts from healthy volunteers (HV, gray squares, n ¼ 13), bone
marrow- (BMT, white triangles, n ¼ 17) and cord blood- transplant recipients
(CBT, black circles, n ¼ 26) patients at 1, 2, 3, 6, 9, and 12 months after
transplantation. (A) Related and unrelated transplant recipients. (B) Unrelated
transplant recipients only. Each symbol represents 1 patient. Horizontal bars
represent the means. A 2-sided Mann-Whitney test was used to compare CBT
patients with BMT patients (P values are indicated at the top of each time-
point) and to healthy volunteers (*P < .05; **P < .01; ***P < .001).
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cyclosporine until 10 months after transplantation. Sup-
portive treatment was as previously described [21] and was
identical for all patients, except for granulocyte colonye
stimulating factor (G-CSF), which was administered only
after CBT from day þ5 until neutrophil recovery.
Immunophenotyping of pDCs
Immunophenotyping was performed on fresh whole
blood samples by ﬂow cytometry (FACSCanto and FACSCali-
bur, BD Biosciences, Mississauga, ON) and data were
analyzed using CellQuest and Diva software (BD Biosciences,
Mississauga, ON). The following antibodies (BD Biosciences)
were used: antilineage (CD3, CD14, CD16, CD19, CD20, and
CD56) FITC, antieHLA-DR PE/Cy7 and antieCD123 APC for
phenotyping, as well as antibodies targeting T cell cos-
timulatory molecules: antieCD40 FITC, antieCD54 PE,
antieCD80 FITC, and antieCD86 PE. A minimum of 50,000
events in the mononuclear cell gate were collected. pDCs
were deﬁned as Lin HLA-DRþ CD123high cells. Absolute pDC
counts were determined by multiplying the percentage of
pDCs among mononuclear cells by the total number of
mononuclear cells [22].
Functional analyses were performed on blood samples
from 15 CB and 12 BM recipients after overnight stimulation
of whole blood with the CpG ODN 2216 oligodeoxynucleo-
tide (50 mg/mL; Midland, TX) or control oligodeoxynucleo-
tide (50 mg/mL; Midland). The increase in expression of
costimulatory molecules (CD40, CD54, CD80, and CD86) was
expressed as: Dmean ﬂuorescence intensity (DMFI ¼MFI of
stimulated cellseMFI of unstimulated cells/MFI of unstimu-
lated cells).
IFN-a Production
IFN-a levels were determined in supernatants using an
enzyme-linked immunosorbent assay (ELISA) kit (PBL
Interferon Source, Piscataway, NJ). Results are expressed as
IFN-a production by stimulated cellseIFN-a production by
unstimulated cells and normalized as per 104 pDCs.
In Vitro pDC Expansion and Differentiation
In vitro pDC expansion and differentiation from he-
matopoietic progenitors were performed using a method
adapted from Chen et al. [23]. CB and BM CD34þ cells were
puriﬁed by positive immunomagnetic selection (Miltenyi
Biotec, Auburn, CA). A quantity of 106 cells/mL was cultured
in Yssel’s medium supplemented with 5% human serum AB
(Gemini Bio-Products, Sacramento, CA), with the addition of
Flt3-ligand (100 ng/mL), thrombopoietin (Tpo) (50 ng/mL),
and stem cell factor (SCF) (10 ng/mL), all from R&D Systems
(Minneapolis, MN). The culture medium was changed every
2 to 3 days. After 1 week of hematopoietic precursor
expansion, SCF was removed and IL-7 (10 ng/mL, Cytheris,
France) was added for 2 additional weeks to favor pDC dif-
ferentiation [24]. pDC counts were evaluated by ﬂow
cytometry with antilineage FITC, antieHLA-DR PE/Cy7, and
antieCD123 APC antibodies.
Statistics
Statistical analyses were performed using Prism (Graph-
Pad Software, San Diego, CA). For the primary objective of the
study, CBT patients were compared with BMT patients and
healthy individuals using a 2-sided Mann-Whitney test for:
(1) pDCs counts in blood, (2) IFN-a production upon stimu-
lation with CpG ODN 2216, and (3) the increase in theexpression of costimulatory molecules upon stimulation
with CpG.
RESULTS
Rapid and Sustained pDC Count Recovery after CBT
Peripheral blood pDCs were counted in children who
underwent BMT and CBT from 1 to 12 months after trans-
plantation. The characteristics of the 2 groups of patients
were similar, except for HLA matching, numbers of infused
cells, and length of thrombocytopenia, as expected (Table 1).
pDC counts measured in blood samples from CBT patients
were similar to those measured in healthy individuals as
early as 1 month after transplantation (Figure 1A). There-
after, pDCs counts were higher than normal until 9 months
after CBT (Figure 1A). pDC counts were higher after CBT than
after BMT from 2 to 9 months after transplantation
(Figure 1A), in agreement with previous reports of low pDC
counts after BMT [17,18]. This difference remained signiﬁcant
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plantations (Figure 1B).
Enhanced Production of pDCs from CD34þ CB Cells
in Vitro
The faster reconstitution of pDC counts after CBT
prompted us to postulate that CB progenitors have a greater
capacity than BM progenitors to give rise to pDCs. Thus, we
cultured CB and BM CD34þ cells in conditions promoting
pDC differentiation. Under similar culture conditions that
included the addition of thrombopoietin, stem cell factor,
fms-like tyrosine kinase receptor-3 ligand, and interleukin 7,
CB CD34þ cells gave rise to a 500-fold increase in pDCs after
21 days of culture over BM CD34þ cells (median, 1.49 $ 106
pDCs from 105 CB CD34þ cells versus 2.95 $ 103 from 105 BM
CD34þ cells; n ¼ 4 BM and n ¼ 10 for CB samples; P ¼ .002)
(Figure 2A,B). In addition, these in vitro CBederived pDCs
produced high levels of IFN-a and expressed costimulatory
receptor ligands upon in vitro stimulation with TLR-9 ago-
nists (Figure 2C,D).Figure 2. In vitro differentiation of functional pDCs from CB and BM-derived CD34þ ce
presence of TPO, SCF, and Flt3-L for 1 week, followed by 1 to 2 weeks of culture in the p
CD34þ cells is represented (n ¼ 4 for BM samples and n ¼ 10 for CB samples). (B)
CD123hiHLA-DRþBDCA2þ cells by ﬂow cytometry. (C) Ten thousand in vitro differenti
CpG ODN 2216 and IFN-a was measured in the supernatant by ELISA. Data are shown
human pDCs were stimulated with CpG ODN 2216. The upregulation of activation m
representative of 3 independent experiments.Normal Upregulation of T Cell Costimulatory Molecules
by Post-transplantation pDCs after TLR-9 Stimulation
We investigated the capacity of post-transplantation
pDCs to mature into antigen-presenting cells. The expres-
sion of T cell costimulatory molecules CD40, CD54, CD80, and
CD86 on pDCs was assessed by ﬂow cytometry 24 hours after
whole blood stimulation with a TLR-9 agonist (CpG ODN).
We observed that CD40, CD54, CD80, and CD86 molecules
are upregulated on post-transplantation pDCs (Figure 3A)
from patients who underwent transplantation with BM and
CB. This upregulation was similar to that seen in normal
healthy volunteers, indicating that pDCs mature normally
into antigen-presenting cells after BMT as well as after CBT.
Impaired IFN-a Production after CBT
We next measured IFN-a in the supernatant of blood
mononuclear cells stimulated with CpG ODN by ELISA. We
normalized the results per 104 pDCs. We observed that IFN-a
production in response to TLR-9 stimulation was impaired in
CBT patients for up to 9 months after transplantationlls. CD34þ cells were puriﬁed from either CB or BM samples and cultured in the
resence of Flt3-L, TPO, and interleukin-7. (A) Total cell expansion of CB and BM-
Human pDCs obtained after 20 days of CD34þ cell culture are identiﬁed as
ated human pDCs were sorted by ﬂow cytometry and stimulated overnight by
at the mean  SEM of 5 independent experiments. (D) In vitro differentiated
arkers (CD80, CD86, CD40, CD54) was assessed by ﬂow cytometry. Data are
Figure 3. Functional analysis of plasmacytoid dendritic cells after cord blood and bone marrow transplantation. (A) Expression of costimulatory molecules after TLR-9
stimulation by CpG 2216 was assessed by ﬂow cytometry in samples from healthy volunteers (HV, gray bars, n ¼ 9), and recipients of BMT (white bars, n ¼ 12) or CBT
(black bars, n ¼ 12). The increase in expression of costimulatory molecules (CD40, CD54, CD80, and CD86) is expressed as Dmean ﬂuorescence intensity (DMFI ¼MFI
of stimulated cells eMFI of unstimulated cells/MFI of unstimulated cells). Results are shown as mean  SEM. Signiﬁcant P values are reported as: *P < .05; **P < .01;
***P < .001. (B) Interferon-alpha (IFN-a) production after overnight toll-like receptor (TLR)-9 stimulation by CpG ODN 2216 was measured in peripheral blood
mononuclear cells of healthy volunteers (HV, gray bars, n ¼ 8), and recipients of bone marrow (BMT, white bars, n ¼ 12) or cord blood transplantation (CBT, black bars,
n ¼ 15). IFN-a production was measured in the supernatants by ELISA. Results are expressed as IFN-a production by stimulated cells - IFN-a production by unsti-
mulated cells and normalized for 104 pDCs. Results are shown as mean  SEM. A 2-sided Mann-Whitney test was used to compare CBT patients with BMT patients
(P values are indicated at the top of each time-point) and healthy volunteers (*P < .05; **P < .01; ***P < .001).
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patients as soon as 1 month after transplantation.
DISCUSSION
This is the ﬁrst longitudinal study of pDC reconstitution
and function after CBT and BMT. In CBT patients, pDC blood
counts were higher than normal from 2 to 9 months after
transplantation, but their IFN-a production in response to
TLR-9 agonist was profoundly impaired. In contrast, in BMT
patients, pDC counts were signiﬁcantly lower, but their IFN-a
production was normal in response to TLR-9 stimulation.
This major difference in the recovery of innate immunity
between BMT and CBT patients has important implications
when it comes to designing post-transplantation innate
immunotherapeutic approaches.
pDC blood counts were higher after CBT than after BMT,
despite a lower stem cell dose in CB grafts and the treatment
of CBT patients with drugs known to decrease pDC counts,
such as corticosteroids, ATG, and G-CSF [17,25,26]. Current
knowledge about pDC lifespan makes it unlikely that post-
transplantation pDCs may arise from the expansion of
mature pDCs present in the graft [27]. In vitro expansion of
pDCs from CD34þ CB cells takes only 3 weeks, suggesting
that post-transplantation pDCs arise instead from engrafted
stem cells. Although a difference in pDC tissue homing
cannot be completely excluded in the absence of tissue bi-
opsies, the difference between post-CBT and post-BMT pDC
counts can be attributed to CB stem cells’ higher capacity to
expand and differentiate into pDCs.
The 2 main functional hallmarks of pDCs are their ability
to rapidly secrete high levels of IFN-a upon TLR stimulation,
followed by the upregulation of T cell costimulatory mole-
cules. Our functional study reveals that although they nor-
mally upregulate T cell costimulatory molecules, post-CBT
pDCs are unable to produce signiﬁcant amounts of IFN-a
for up to 9 months after transplantation. Two hypotheses
could explain this impaired IFN-a production after CBT. ATG,
corticosteroids, and G-CSF given to CBT, but not to BMT pa-
tients, may interfere with IFN-a production [17,25,26]. This,
however, does not explain why IFN-a production remained
low for more than 6 months after the cessation of these
drugs. A prolonged effect of ATG cannot be completely ruled
out, although this effect would have been expected to affect
pDC numbers rather than their functions, as described for
other immune cells [28]. pDC-impaired function is more
likely related to the stem cell source itself. Indeed, we and
others have shown that pDCs present in CB are characterized
by the combination of an absence of IFN-a production with
normal upregulation of T cell costimulatory molecules upon
TLR-9 stimulation [29,30]. Furthermore, it has recently been
shown that IFN-a production is impaired in infant mice [31].
Similarly, humanized mice reconstituted with fetal human
hematopoietic progenitors fail to produce IFN-a upon TLR-9
stimulation [32]. Of note, although this impairment is
observed in different in vivo models, we show here that
in vitro expansion and differentiation of CB CD34þ cells leads
to functional pDCs that are able to produce high amounts of
IFN-a, upregulate T cell costimulation molecules, and acti-
vate innate immune cells.
The lower capacity of post-CBT pDCs to produce IFN-a in
response to TLR-9 stimulation may contribute to the higher
rates of opportunistic infections and lower rates of GVHD
observed after CBT [20,21,33]. Our study was not, however,
designed to test this hypothesis and, therefore, there weretoo few patients in our cohort to establish a correlation
among pDC counts, defects in IFN-a production, and oppor-
tunistic infection or GVHD rates. Similarly, our study was not
designed to correlate pDC counts or function with graft or
patient characteristics or other clinical outcomes. Larger
clinical studies of pDC reconstitution would be needed to
assess these correlations.
The unique characteristics of post-CBT pDCs should be
taken into account in the development of immunothera-
peutic strategies based on TLR-9 stimulation after HSCT [8].
Indeed, CpG ODN treatment of leukemia-bearing mice has
been shown to prevent leukemia onset and provide long-
term protection against leukemia [10]. This antileukemia
effect has been shown to be mediated by early activation of
innate effectors such as dendritic cells, macrophages, and NK
cells, followed by T cell adaptive immune responses for long-
term control of the disease [8,10,11]. The correlation between
the eradication of leukemia cells and the high amounts of
IFN-a and IL-12 in CpG ODNetreated mice suggests that
dendritic cells and, in particular, pDC activation are required
to mount NK and T cell responses [8]. These studies led to
an ongoing phase I clinical trial studying GNKG168, a
TLR-9 agonist, in children with refractory acute leukemia,
including patients after HSCT (NCT01743807). The IFN-
aemediated activation of NK cells is expected to play a major
role in the effect of TLR agonists after CBT, as patients lack
functional T cells for the ﬁrst months after transplantation,
when the leukemia burden is at its lowest [34e36]. Our re-
sults indicate that CpG ODN treatment is not expected to
induce IFN-a production by pDCs in CBT patients, thereby
limiting its ability to prevent or control leukemia relapse in
these patients.
Taken together, our results show that although blood pDC
counts rapidly increase over normal values after CBT, their
ability to secrete IFN-a upon TLR-9 activation is severely
impaired. Future attempts of post-transplantation pDC acti-
vation to prevent leukemia relapse must take this impair-
ment into account. An alternative to TLR-9 agonists is the use
of adoptive transfer of activated pDCs. Adoptive transfer of
activated pDCs has already been tested in adult patients with
melanoma in a phase I clinical trial and the results demon-
strated that infusions of activated pDCs induced favorable
immune responses withminimal toxicity [37,38]. In addition,
our method of in vitro expansion and differentiation of high
numbers of functional pDCs from CB progenitors paves the
way for such adoptive transfer of activated pDCs in the pre-
vention of leukemia relapse after CBT.ACKNOWLEDGMENTS
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